[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

187 Oral Rivaroxaban for the Acute and Continued Treatment of Symptomatic Venous Thromboembolism. the Einstein-DVT and Einstein-Extension StudyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: Antithrombotic Therapy: Changing Practice Through Clinical Trials - Antithrombotics and Reversing Agents
Monday, December 6, 2010: 7:00 AM
230 (Orange County Convention Center)

Harry Roger Buller, MD, PhD

Dept of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands

Background New oral anticoagulants hold the promise of simple fixed-dose regimens without the need for monitoring and could make extended use more attractive. Current guidelines advise indefinite therapy in a substantial proportion of DVT patients. The Einstein-DVT study was designed to compare rivaroxaban, a direct oral factor Xa inhibitor, to enoxaparin followed by oral vitamin K antagonist (VKA) treatment in patients with acute DVT for either 3, 6, or 12 months. In Einstein-Extension, patients who had completed 6 to 12 months of anticoagulant treatment for either DVT or PE were randomized to receive rivaroxaban or placebo for an additional 6 or 12 months.

Study Design Einstein-DVT was an open label, event-driven (target 88 confirmed recurrent VTEs) non-inferiority study. Subjects with a confirmed acute symptomatic DVT without symptomatic PE were randomized to receive either oral rivaroxaban 15 mg twice-daily for 3 weeks followed by 20 mg once-daily or initial treatment with enoxaparin (1 mg/kg twice daily) followed by oral VKA treatment (warfarin or acenocoumarol, target INR 2.5, range 2.0 to 3.0). Einstein-Extension was a randomized, double-blind, event-driven (target 30 confirmed recurrent VTEs), placebo-controlled, superiority study that evaluated rivaroxaban 20 mg once-daily for an additional 6 or 12 months. The primary efficacy outcome for both studies was recurrent non-fatal or fatal symptomatic venous thromboembolism (VTE). The principal safety outcome was clinically relevant bleeding (major or clinically relevant non-major bleeding) in Einstein-DVT and major bleeding only in Einstein-Extension. All study outcomes were adjudicated by a central and blinded committee.

Results Einstein-DVT: the ITT-population consisted of 1,731 rivaroxaban and 1,718 enoxaparin/VKA recipients and rivaroxaban demonstrated non-inferior efficacy to enoxaparin/VKA for the primary outcome (rivaroxaban 36 events (2.1%), enoxaparin/VKA 51 events (3.0%), hazard ratio (HR), 0.68; 95% CI 0.44 –1.04, p <0.0001 for non-inferiority, 0.076 for superiority). Major and non-major clinically relevant bleeding occurred in 8.1% of subjects in both treatment groups (HR 0.97; 95% CI 0.76 –1.22, p =0.77) and major bleedings occurred in 14 (0.8%, 1 fatal) and 20 (1.2%, 5 fatal) of the rivaroxaban and enoxaparin/VKA recipients, respectively (HR 0.65; 95% CI 0.33 -1.28, p =0.21). The net clinical benefit defined as the primary efficacy outcome plus major bleeding showed a HR of 0.67 (95% CI 0.47 – 0.95; p=0.027). In the rivaroxaban group, 38 (2.2%) subjects died versus 49 (2.9%) in the enoxaparin/VKA group (HR 0.67; 95% CI 0.44 – 1.02). The time spent in the therapeutic INR range during VKA treatment was 58%. Einstein-Extension: the ITT population consisted of 602 rivaroxaban and 594 placebo subjects and rivaroxaban demonstrated superiority to placebo for the primary outcome (rivaroxaban 8 events (1.3%), placebo 42 events (7.1%), HR 0.18; 95% CI, 0.09 - 0.39; p<0.0001; number needed to treat: 15) over a mean study treatment period of approximately 6.5 months. Major bleeding did not occur in placebo subjects and was observed in 4 (0.7%, none were fatal) rivaroxaban subjects (p=0.11). Clinically relevant non-major bleeding was noted in 7 (1.2%) and 32 (5.4%) of the placebo and rivaroxaban recipients, respectively (p<0.0001). Two (0.3%) patients in the placebo group died versus 1 (0.2%) in the rivaroxaban group. Efficacy and safety results were consistent across all pre-specified subgroups in both studies.

Conclusions Against a background of prolonging anticoagulant treatment for many months to years, this study indicates that oral rivaroxaban, 15 mg twice-daily for 3 weeks followed by 20 mg once-daily, could provide clinicians and patients with a simple, single-drug approach for the acute and continued treatment of DVT that potentially improves the benefit–risk profile of anticoagulation.

Disclosures: Buller: Bayer Schering Pharma: Consultancy, Research Funding.

Previous Abstract | Next Abstract >>

*signifies non-member of ASH